Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24 Phase 1 and Phase 3 studies expected to be completed within 2026 INCHEON, Korea — Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a [...]